PPIs and gastric cancer: any causal relationship?
Keywords:
PPIs, Gastric cancer, Atrophic gastritis, Helicobacter pylori, Intestinal metaplasiaAbstract
Hydrochloric acid is crucial in gastric physiology. In 1978 cimetidine, the first H2 antagonist of histamine receptors on the gastric parietal cell was introduced into therapy, inducing acid.
Lasting the years, several studies focused on the potential relationship between inducing hypo-achlorhydria and risk of developing gastric cancer. In 1988 omeprazole, the first proton pump inhibitor, entered therapy.
In 1996, Kuipers underlined the danger of progression of chronic atrophic gastritis in subjects taking PPIs. In 2018, one paper from Korea and an another on from Sweden suggested a possible relationship between long-term PPI therapy and the development of gastric cancer. Over the years, several articles, meta-analyzes and population based focused on relationship between long-term of PPI use and the onset of gastric cancer, with conflicting results. As reported, the presence of bias in the collection of cases, in particular concerning the evaluation of the H.p. status and presence of atrophic gastritis and intestinal metaplasia in subjects treated with PPI, can lead to noticeable errors in the results and conclusions, as demonstrated in the literature by exhaustive methodological studies of pharmacoepidemiology.
A possible bias in the collection of case histories is due to the fact that PPIs are often administered to dyspeptic patients, among which there are patients already carriers of gastric neoplasia: the so-called inverse causality. Literature data, amended by methodological bias (sampling errors, lack of comparative assessment of Hp status and atrophic gastritis) NOT support a causal relationship between long-term PPIs therapy and the onset of gastric cancer
References
Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut. 2015 Oct;64(10):1650-68.
El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology. 1995 Sep;109(3):681-91.
Shin JM, Vagin O, Munson K, Kidd M, Modlin IM, Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci. 2008 Jan;65(2):264-81. doi: 10.1007/s00018-007-7249-x. Erratum in: Cell Mol Life Sci. 2011 Mar;68(5):921.
Mignon M, Bonfils S. Diagnosis and treatment of Zollinger-Ellison syndrome. Baillieres Clin Gastroenterol. 1988 Jul;2(3):677-98.
Battaglia G, Farini R, Di Mario F, et al. Recurrence of duodenal ulcer under continuous antisecretory treatment: an approach to the detection of predictive markers. Am J Gastroenterol. 1984 Nov;79(11):831-4.
Zamcheck N, Grable E, Ley A, Norman L. Occurrence of gastric cancer among patients with pernicious anemia at the Boston City Hospital. N Engl J Med. 1955 Jun 30;252(26):1103-10.
Langman MJ. Antisecretory drugs and gastric cancer. Br Med J (Clin Res Ed). 1985 Jun 22; 290 (6485): 1850-2.
Brogden RN, Heel RC, Speight TM, Avery GS. Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs. 1978 Feb;15(2):93-131.
Sontag S, Graham DY, Belsito A et al. Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. N Engl J Med. 1984 Sep 13;311(11):689-93.
Brunner H, Dittrich H, Kratochvil P et al. Treatment of duodenal ulcer with pirenzepine and cimetidine. Gut. 1984 Feb;25(2):206-10.
La Vecchia C, Negri E, D'Avanzo B, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet. 1990 Aug 11;336(8711):355-7.
Taylor TV, Lee D, Howatson AG, Anderson J, MacLeod IB. Gastric cancer in patients who have taken cimetidine. Lancet. 1979 Jun 9;1(8128):1135-6.
Elder JB, Ganguli PC, Gillespie IE. Cimetidine and gastric cancer. Lancet. 1979 May 12;1(8124):1005-6.
Ruddell WS. Gastric cancer in patients who have taken cimetidine. Lancet. 1979 Jun 9;1(8128):1234.
Reed PI, Cassell PG, Walters CL. Gastric cancer in patients who have taken cimetidine. Lancet. 1979 Jun 9;1(8128):1234-5.
Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-715.
Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995 Oct 26;333(17):1106-10.
Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol. 1988 Jun;23(5):625-32.
Hetzel DJ, Dent J, Reed WD et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988 Oct;95(4):903-12.
Klinkenberg-Knol EC, Jansen JB, Lamers CB, Nelis F, Snel P, Meuwissen SG. Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists. Scand J Gastroenterol Suppl. 1989;166:88-93; discussion 94.
Meuwissen SG, Craanen ME, Kuipers EJ. Gastric mucosal morphological consequences of acid suppression: a balanced view. Best Pract Res Clin Gastroenterol. 2001 Jun;15(3):497-510.
Bockus's Gastroenterology, 2rd Ed.,1963, pag. 748
Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988 Jul 1;48(13):3554-60.
Rugge M, Genta RM, Di Mario F, El-Omar EM, El-Serag HB, Fassan M, Hunt RH, Kuipers EJ, Malfertheiner P, Sugano K, Graham DY. Gastric Cancer as Preventable Disease. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1833-1843. doi: 10.1016/j.cgh.2017.05.023. Epub 2017 May 19.
GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2020 Cancer Today (iarc.fr)
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23. PMID: 25079317;
IARC. IARC monographs on the evaluation of carcinogenic risks to humans. 2022: Monographs available – IARC Monographs on the Identification of Carcinogenic Hazards to Humans (who.int)
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000 Mar 23;404(6776):398-402. doi: 10.1038/35006081. Erratum in: Nature 2001 Jul 5;412(6842):99.
Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014 Apr 10;345(2):196-202. doi: 10.1016/j.canlet.2013.08.016. Epub 2013 Aug 24.
Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016 May;150(5):1113-1124.e5. doi: 10.1053/j.gastro.2016.01.028. Epub 2016 Feb 2
Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: Can Helicobacter pylori eradication treatment reduce the risk of gastric cancer? Ann Intern Med. 2009; 151:121–8.
Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomized controlled trials. BMJ. 2014; 348:g3174.
De Witte C, Schulz C, Smet A, Malfertheiner P, Haesebrouck F. Other Helicobacters and gastric microbiota. Helicobacter. 2016 Sep;21 Suppl 1:62-8. doi: 10.1111/hel.12343.
Schulz C, Schütte K, Mayerle J, Malfertheiner P. The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond. Therap Adv Gastroenterol. 2019 Dec 18;12:1756284819894062. doi: 10.1177/1756284819894062. PMID: 31897087;
Schulz C, Schütte K, Malfertheiner P. Helicobacter pylori and Other Gastric Microbiota in Gastroduodenal Pathologies. Dig Dis. 2016;34(3):210-6. doi: 10.1159/000443353. Epub 2016 Mar 30.
Vermeer IT, Engels LG, Pachen DM, et al. Intragastric volatile N-nitrosamines, nitrite, pH, and Helicobacter pylori during long-term treatment with omeprazole. Gastroenterology. 2001; 121:517–25.
Sugano K. Premalignant conditions of gastric cancer. J Gastroenterol Hepatol. 2013; 28:906–11.
Wu MS, Shun CT, Wu CC, et al. Epstein-Barr virus-associated gastric carcinomas: Relation to H. pylori infection and genetic alterations. Gastroenterology. 2000; 118:1031–8
Pizzi M, Saraggi D, Fassan M, et al. Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori-associated gastritis. Dig Dis. 2014; 32:265–74
Rugge M, Pennelli G, Pilozzi E, et al. Gastritis: the histology report. Dig Liver Dis. 2011; 43(Suppl 4):S373–84
Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014; 20:5191–204.
Rugge M, Capelle LG, Cappellesso R, et al. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013; 27:205–23.
Rugge M, Fassan M, Graham DY. Clinical guidelines: Secondary prevention of gastric cancer. Nat Rev Gastroenterol Hepatol. 2012; 9:128–9.
Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005; 36:228–33.)
Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010; 71:1150–8.
Rugge M, Genta RM, Group O. Staging gastritis: an international proposal. Gastroenterology. 2005; 129:1807–8.
Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010; 31:1104–11.
Daugule I, Sudraba A, Chiu HM, et al. Gastric plasma biomarkers and Operative Link for Gastritis Assessment gastritis stage. European J Gastroenterol Hepatol. 2011; 23:302–7.
den Hoed CM, Holster IL, Capelle LG, de Vries AC, den Hartog B, Ter Borg F, Biermann K, Kuipers EJ. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy. 2013;45(4):249-56. doi: 10.1055/s-0032-1326379. Epub 2013 Mar 26.
Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007; 56:631–6.
Malfertheiner P, Megraud F, Rokkas T, et al; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8:gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745. Epub ahead of print. PMID: 35944925.
Sugano K, Tack J, Kuipers EJ, et al. The Kyoto Global Consensus Report on Helicobacter pylori gastritis. Gut. 2015; 64:1353–67.
Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2009; 15:1–16
Burkitt MD, Pritchard DM (2006) Review article: pathogenesis and management of gastric carcinoid tumors. Aliment Pharmacol Ther 24: 1305–1320. doi:10.1111/j.1365-2036.2006.03130.x..
2. Modlin I, Lye K, Kidd M (2004): A 50 year analysis of 562 gastric carcinoids: small tumor or larger problem? Ann J Gastroenterol 99: 23–32
Dockray GJ, Varro A, Dimaline R, et al. The gastrins: their production and biological activities. Ann Rev Physiol. 2001; 63:119–39
Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther. 1998; 12:605–12
Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther. 1998; 12:605–12.
Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 2000; 118:36–47.
Fox JG, Rogers AB, Ihrig M, et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res. 2003; 63:942–50.
Lofgren JL, Whary MT, Ge Z, et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology. 2011; 140:210–20.
Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P, Nelis GF, Meuwissen SG. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996 Apr 18;334(16):1018-22.
Farinati F, Cardin R, Libera GD, Rugge M, Herszènyi L, Di Mario F, Molari A, Plebani M, Naccarato R. Determinants for the development of chronic atrophic gastritis and intestinal metaplasia in the stomach. Eur J Cancer Prev. 1995 Apr;4(2):181-6.
Meuwissen SG, Craanen ME, Kuipers EJ. Gastric mucosal morphological consequences of acid suppression: a balanced view. Best Pract Res Clin Gastroenterol. 2001 Jun; 15 (3): 497-510. doi: 10.1053 / bega.2001.0189.
Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018 Jan; 67 (1): 28-35.
Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017 Oct 30; 7 (10): e017739
Niikura R, Hayakawa Y, Hirata Y, Yamada A, Fujishiro M, Koike K. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut. 2018 Oct;67(10):1908-1910.
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015 Sep;42(6):649-63.
Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013 Apr 28; 19 (16): 2560-8.
Lee JK, Merchant SA, Schneider JL, Jensen CD, Fireman BH , Quesenberry CP, Corley DA. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. Am J Gastroenterol. 2020 May; 115 (5): 706-715.
Jiang K, Jiang X, Wen Y, Liao L, Liu FB. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. J Gastroenterol Hepatol. 2019 Nov; 34 (11): 1898- 1905. doi: 10.1111 / jgh.14759. Epub 2019 Jul 24. PMID: 31206764.
Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009 Mar;59(3):135-53
GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2020 Cancer Today (iarc.fr)
Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008 Feb 15; 167 (4): 492-9. Doi: 10.1093 / aje / kwm324. Epub 2007 Dec 3. PMID: 18056625.) (Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580–4.
Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20:819–25.
Adams RJ, Fuhlbrigge AL, Finkelstein JA, et al. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002;109:636–42.
Liu P, McMenamin ÚC, Johnston BT, Murchie P, Iversen L, Lee AJ, Vissers PAJ, Cardwell CR. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. Br J Cancer. 2020 Jul;123(2):307-315. doi: )10.1038/s41416-020-0860-4. Epub 2020 May 5. PMID: 32367073; PMCID: PMC7374738.
Jiang, K., Jiang, X., Wen, Y., Liao, L. & Liu, F. Relationship between long‐term use of proton pump inhibitors and risk of gastric cancer: a systematic analysis. J. Gastroenterol. Hepatol. 34, 1898–1905 (2019).
Ahn, J. S., Eom, C.-S., Jeon, C. Y. & Park, S. M. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J. Gastroenterol. 19, 2560–2568 (2013).
Crane, S. J., Locke, G. R., Harmsen, W. S., Diehl, N. N., Zinsmeister, A. R., Melton, L. J.et al. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am.J. Gastroenterol. 102, 1596–1602 (2007).
Niikura, R., Hayakawa, Y., Hirata, Y., Yamada, A., Fujishiro, M. & Koike, K. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: A retrospective cohort analysis. Gut 67, 1908–1910 (2018).
Pottegård, A., Friis, S., Stürmer, T., Hallas, J. & Bahmanyar, S. Considerations for pharmacoepidemiological studies of drug-cancer associations. Basic Clin. Pharmacol. Toxicol. 122, 451–459 (2018).
Correa, P. & Piazuelo, M. B. The gastric precancerous cascade. J. Dig. Dis. 13, 2–9 (2012).
Griffin, S. M. & Raimes, S. A. Proton pump inhibitors may mask early gastric cancer. Br. Med. J. 317, 1606–1607 (1998).
Pottegård, A., Friis, S., Stürmer, T., Hallas, J. & Bahmanyar, S. Considerations for pharmacoepidemiological studies of drug-cancer associations. Basic Clin. Pharmacol. Toxicol. 122, 451–459 (2018).
Corley, D. A. Safety and complications of long-term proton pump inhibitor therapy: getting closer to the truth. Gastroenterology 157, 604–607 (2019).
Liu P, McMenamin ÚC, Johnston BT, Murchie P, Iversen L, Lee AJ, Vissers PAJ, Cardwell CR. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. Br J Cancer. 2020 Jul; 123 (2): 307-315. Doi: 10.1038 / s41416-020-0860-4. Epub 2020 May 5. PMID: 32367073; PMCID: PMC7374738.
Savarino V, Tosetti C, Benedetto E, Compare D, Nardone G. Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) - Study section "Digestive Diseases in Primary Care". Dig Liver Dis. 2018 Sep;50(9):894-902. doi: 10.1016/j.dld.2018.07.004. Epub 2018 Jul 17. PMID: 30093304.
Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov 9; 14 (1): 179. Doi: 10.1186 / s12916-016-0718-z. PMID: 27825371; PMCID: PMC5101793.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Pellegrino Crafa, Marilisa Franceschi, Kryssia Isabel Rodriguez-Castro, Lorella Franzoni, Michele Russo, Giovanni Brandimarte, Antonio Tursi, Massimo Rugge, Francesco Di Mario
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
